We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
-9.15%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.68B
AUM Growth
-$780M
Cap. Flow
-$238M
Cap. Flow %
-14.17%
Top 10 Hldgs %
50.05%
Holding
96
New
8
Increased
9
Reduced
34
Closed
18

Top Buys

Rank Stock Value
1
BEAM icon
Beam Therapeutics
BEAM
+$34.2M
2
VERV
Verve Therapeutics
VERV
+$16.8M
3
VTYX
Ventyx Biosciences
VTYX
+$14.9M
4
CCXI
ChemoCentryx, Inc.
CCXI
+$14M
5
TNGX icon
Tango Therapeutics
TNGX
+$12M

Top Sells

Rank Stock Value
1
AVIR icon
Atea Pharmaceuticals
AVIR
+$50.6M
2
AGEN
Agenus
AGEN
+$25.2M
3
RVMD icon
Revolution Medicines
RVMD
+$20.1M
4
OLMA icon
Olema Pharmaceuticals
OLMA
+$18.7M
5
ASND icon
Ascendis Pharma A/S
ASND
+$17.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCKT icon
26
Rocket Pharmaceuticals
RCKT
$387M
$19M 1.13%
868,550
-100,000
-10% -$2.73M
TRML
27
DELISTED
Tourmaline Bio
TRML
$18.1M 1.08%
118,255
-3,330
-3% -$493K
AXNX
28
DELISTED
Axonics, Inc. Common Stock
AXNX
$18M 1.07%
322,240
– –
ALXO icon
29
ALX Oncology
ALXO
$284M
$16.4M 0.97%
762,079
-250,000
-25% -$10.8M
VTYX
30
DELISTED
Ventyx Biosciences
VTYX
$15.1M 0.9%
+785,303
New +$14.9M
AVIR icon
31
Atea Pharmaceuticals
AVIR
$399M
$15M 0.89%
1,679,442
-3,249,314
-66% -$50.6M
PRAX icon
32
Praxis Precision Medicines
PRAX
$10.3B
$14.8M 0.88%
50,160
-18,117
-27% -$5.31M
IGMS
33
DELISTED
IGM Biosciences
IGMS
$14.7M 0.87%
500,000
+150,000
+43% +$7.45M
CCXI
34
DELISTED
ChemoCentryx, Inc.
CCXI
$14.6M 0.87%
+400,000
New +$14M
GHRS icon
35
GH Research
GHRS
$2.1B
$14.2M 0.84%
608,123
– –
ACET icon
36
Adicet Bio
ACET
$74.2M
$13.1M 0.78%
+46,875
New +$8.04M
ACRS icon
37
Aclaris Therapeutics
ACRS
$851M
$13.1M 0.78%
900,000
-600,000
-40% -$9.09M
ELEV
38
DELISTED
Elevation Oncology
ELEV
$11.9M 0.71%
1,983,165
– –
TYRA icon
39
Tyra Biosciences
TYRA
$1.61B
$11.6M 0.69%
839,932
-230,000
-21% -$4.57M
LBPH
40
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$11.1M 0.66%
2,273,221
– –
MRTX
41
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$11M 0.65%
75,000
-45,000
-38% -$6.99M
VECT
42
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$10.9M 0.65%
2,216,763
-9,365
-0.4% -$46.2K
PHVS icon
43
Pharvaris
PHVS
$2.41B
$9.93M 0.59%
689,731
– –
ZYME icon
44
Zymeworks
ZYME
$1.7B
$9.83M 0.58%
600,000
-350,000
-37% -$7.3M
ICVX
45
DELISTED
Icosavax, Inc. Common Stock
ICVX
$9.76M 0.58%
426,393
– –
KROS icon
46
Keros Therapeutics
KROS
$211M
$8.78M 0.52%
+150,000
New +$7.48M
AKRO
47
DELISTED
Akero Therapeutics
AKRO
$8.54M 0.51%
403,787
-196,213
-33% -$4.35M
PYXS icon
48
Pyxis Oncology
PYXS
$238M
$7.12M 0.42%
+668,854
New +$7.66M
ITOS
49
DELISTED
iTeos Therapeutics
ITOS
$6.98M 0.42%
150,000
-138,330
-48% -$4.6M
ASND icon
50
Ascendis Pharma A/S
ASND
$16.4B
$6.73M 0.4%
50,000
-120,000
-71% -$17.8M
1
2
3 4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q4 2021 Portfolio in Review

As of Q4 2021, Cormorant Asset Management held 96 positions worth $1.68B, down 32% from $2.46B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Cormorant Asset Management withdrew a net $238M in Q4 2021, closing 18 positions and reducing 34 holdings. Its most notable exit was Agenus, an estimated $25.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

Against the trend, Cormorant Asset Management opened a new position in Ventyx Biosciences worth $15.1M.

  • Cormorant Asset Management's largest Q4 2021 buy was Ventyx Biosciences: 785,303 shares worth $15.1M.
  • Cormorant Asset Management added most to Beam Therapeutics in Q4 2021, an estimated $34.2M increase.
  • Cormorant Asset Management's biggest Q4 2021 reduction was Atea Pharmaceuticals, cutting an estimated $50.6M.
  • Cormorant Asset Management fully exited Agenus in Q4 2021, selling an estimated $25.2M.
  • Cormorant Asset Management's ten largest holdings make up 50% of its $1.68B portfolio in Q4 2021.
  • Cormorant Asset Management opened 8 new positions and closed 18 in Q4 2021.
  • Cormorant Asset Management's portfolio value fell 32% quarter-over-quarter to $1.68B.

Based on Cormorant Asset Management's 13F filing for Q4 2021, filed 14 Feb 2022.